Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum

16 Jan 2012

Abstract excerpt

Huntington's disease is caused by expression of a mutant form of Huntingtin protein containing an expanded polyglutamine repeat. One possible treatment for Huntington's disease may be to reduce expression of mutant Huntingtin in the brain via RNA interference. Unless the therapeutic molecule is designed to be allele-specific, both wild-type and mutant protein will be suppressed by an RNA interference treatment. A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Neurodegenerative Diseases
Share to Mitochondrial Function and Pathology
Share to Neurological disorders and treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22252996
DOI: 10.1093/brain/awr333

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatumPMID 22252996Read ↗

AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.Semantic proximity Read ↗

A novel rhesus macaque model of Huntington’s disease recapitulates key neuropathological changes along with progressive motor and cognitive declineSemantic proximity Read ↗

Sustained effects of nonallele-specific Huntingtin silencing.Semantic proximity Read ↗

Intra-striatal AAV2.retro administration leads to extensive retrograde transport in the rhesus macaque brain: implications for disease modeling and therapeutic developmentSemantic proximity Read ↗

Optimized AAV capsids for diseases of the basal ganglia show robust potency and distribution in adult nonhuman primatesSemantic proximity Read ↗

Therapeutic reversal of Huntington’s disease by in vivo self-assembled siRNAsSemantic proximity Read ↗

AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.Semantic proximity Read ↗

Cellular Analysis of Silencing the Huntington’s Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 MiceSemantic proximity Read ↗

Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson’s diseaseSemantic proximity Read ↗

Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.Semantic proximity Read ↗

Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates.Semantic proximity Read ↗

Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.